Publication Year

Thompson CM, Bichteler A, Rager JE, Suh M, Proctor DM, Haws LC, Harris MA. 2016. Comparison of in vivo genotoxic and carcinogenic potency to augment mode of action analysis: Case study with hexavalent chromium. Mut Res/Genet Toxicol Environ Mutagen 800-801(April):28-34; doi: 10.1016/j.mrgentox.2016.01.008.

Garabrant DH, Alexander DD, Miller PE, Fryzek JP, Boffetta P, Teta MJ, Hessel PA, Craven VA, Kelsh MA, Goodman M. 2016. Response to Kay Teschke. Re: Mesothelioma among motor vehicle mechanics: An updated review and meta-analysis. Ann Occup Hyg 60(8):1036-1037; doi: 10.1093/annhyg/mew038.

Thompson CM, Rager JE, Suh M, Ring CL, Proctor DM, Haws LC, Fry RC, Harris MA. 2016. Transcriptomic responses in the oral cavity of F344 rats and B6C3F1 mice following exposure to Cr(VI): Implications for risk assessment. Environ Molec Mutagen 57(9):706-716; doi: 10.1002/em.22064. PMID: 27859739.

Wikoff D, Suh M, Harvey S, Proctor D, Beretvas T, Goodman M, Lipworth L. 2016. Systematic review and meta-analysis of occupational exposure to Cr(VI) and stomach cancer. PROSPERO 2016:CRD42016051625 Available from http://www.crd.york.ac.uk/PROSPERO/display_record.asp?ID=CRD42016051625

Alexander DD, Yan J, Bylsma LC, Northington RS, Grathwohl D, Steenhout P, Erdmann P, Spivey-Krobath E, Haschke F. 2016. Growth of infants consuming whey-predominant term infant formulas with a protein content of 1.8 g/100 kcal: A multicenter pooled analysis of individual participant data. Am J Clin Nutr 104(4):1083-1092.

Thompson CM, Suh M, Mittal L, Wikoff D, Welsh B, Proctor DM. 2016. Development of linear and threshold no significant risk levels for inhalation exposure to titanium dioxide using systematic review and mode of action considerations. Regul Toxicol Pharmacol 80(Oct):60-70; doi: 10.1016/j.yrtph.2016.05.031. PMID: 27233922.

Cetin K, Callaghan F, Fryzek J, Bylsma L, Bezold C, Mehta B. Safety and efficacy/effectiveness of 2nd-line treatments in Immune Thrombocytopenia (ITP): A systematic review of the literature. Presented at the 32nd International Conference on Pharmacoepidemiology & Therapeutic Risk Management, Dublin, Ireland, August 2016.

Nicholson G, Gandra SR, Halbert RJ, Richhariya A, Nordyke RJ. 2016. Patient-level costs of major cardiovascular conditions: A review of the international literature. Clinicoecon Outcomes Res 21(8):495-506; doi: 10.2147/CEOR.S89331. PMID: 27703385.

Lowe KA, Danese MD, Gleeson ML, Langeberg WJ, Kelsh MA. 2016. Racial and ethnic variability in the prevalence and incidence of comorbidities associated with gastric cancer in the United States. J Gastrointest Cancer 47(2):168–181; doi: 10.1007/s12029-016-9809-5.

Erichsen R, Kelsh MA, Oliner KS, Nielsen KB, Frøslev T, Lænkholm AV, et al. 2016. Prognostic impact of tumor MET expression among patients with stage IV gastric cancer: A Danish cohort study. Annals of Epidemiol 26(7):500–503.